Mixed manufacturing results of different improved drugs per product

Leading improved drugs which positioned in the top 10 manufacturing performance list last year, faced mixed results in the first half.

According to the first half’s manufacturing results reported to the Ministry of Food and Drug Safety, the supply of ‘Amosartan,’ a Hanmi Pharms’ anti-hypertensive which recording the largest manufacturing result, was significantly decreased.

Moreover, Otsuka’s...